Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Ricky TirtakusumaDepartment of Host-Microbe Interactions, St Jude Children's Research Hospital, Memphis, TN, USA.
Mohamed A GhonimDepartment of Host-Microbe Interactions, St Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0001-9404-2698
Stefan SchattgenDepartment of Host-Microbe Interactions, St Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-6860-5079
Bradley MullerDepartment of Host-Microbe Interactions, St Jude Children's Research Hospital, Memphis, TN, USA.
Lee Ann Van de VeldeDepartment of Host-Microbe Interactions, St Jude Children's Research Hospital, Memphis, TN, USA.
Tanya M KhanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Jeremy Chase CrawfordDepartment of Host-Microbe Interactions, St Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0003-4096-6048
Jing MaDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Sherif AbdelhamedDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Kasi VegesanaDepartment of Host-Microbe Interactions, St Jude Children's Research Hospital, Memphis, TN, USA.
Walid AwadDepartment of Host-Microbe Interactions, St Jude Children's Research Hospital, Memphis, TN, USA.
E Kaitlynn AllenDepartment of Host-Microbe Interactions, St Jude Children's Research Hospital, Memphis, TN, USA.
Ilaria IacobucciDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0003-2008-1365
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0002-1871-1850
Jeffery M KlcoDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0003-2961-6960
Paul G ThomasDepartment of Host-Microbe Interactions, St Jude Children's Research Hospital, Memphis, TN, USA. paul.thomas@stjude.org.ORCID 0000-0001-7955-0256
Funding
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Shondra Michelle Miller · 1985 to 2026
$166.9M
Translating genomic discoveries to improved outcomes for high risk acute leukemiaR35CA197695 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Charles G Mullighan · 2017 to 2026
$11.4M
DECODING THE INTERACTIONS BETWEEN T CELL RECEPTORS AND PEPTIDE-MHCR01AI136514 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Paul G. Thomas · 2018 to 2026
$6.9M
Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular CarcinomaR01CA265009 · NCI · JOHNS HOPKINS UNIVERSITY · PI Paul G. Thomas, Mark Yarchoan · 2022 to 2026
$3.6M
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) R01AI136514NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA265009NCI NIH HHS R35 CA197695NIAID NIH HHS R01 AI136514U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA265009
6 · The paper itself
Abstract
Pediatric patients with fusion-driven leukemias frequently have a poor prognosis and need more effective therapies. Adoptive T-cell therapies, using expanded autologous T cells, have shown promise as an immunotherapeutic for patients with tumors characterized by high mutational burdens. However, this approach has not been shown to be effective in pediatric leukemias. In this study, we analyzed samples from pediatric patients with fusion-driven acute lymphoblastic, acute myeloid, and mixed phenotypic leukemias, including those with KMT2A-rearrangements. T cells were attained from bone marrow samples, expanded, and their reactivity against autologous leukemic blasts was tested. Strikingly, we observed leukemia-reactive T cells in nearly all patients (33 of 34) at diagnosis or relapse. Furthermore, some patients contained clones reactive to fusion neoantigens and other tumor-associated antigens, and candidate samples were further enriched by selecting for PD1
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Endogenous T cell responses to fusion-derived neoantigens in pediatric acute leukemias. · full record | OpenQuestion